The FDA gives an orphan drug designation to drug candidates that treat a disease that affects less than 200,000 persons in the United States.
The designation is designed to give financial incentives to drugmakers so that drugs for rare diseases will be developed. Those include:
- A 50% tax credit on clinical trial costs
- A break from paying Prescription Drug User Fee Act fees
- The all-important seven years of exclusive sales
Related Fool Articles
Recent Mentions on Fool.com
- 3 Companies Growing Faster Than MannKind Corporation
- Twitter's Favorite Biotech and Pharma Stocks
- Why Opko Health Inc.'s Shares Got a Shot to the Arm Today
- George Soros Bought Stock in This Small Biotech: Should You?
- It's Not the Zombie Apocalypse, but Killer Superbugs Could Be on the Way
- GlaxoSmithKline vs. Sanofi: Which Is The Better Dividend Stock?